AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Jun 4, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-05-31

Reporting Person: Foster-Cheek Kaye I (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-31	Stock option (right to buy)	$93.50	A	5700	Acquired	2028-05-30	Common stock (5700)	Direct
2018-05-31	Restricted stock units	$	A	1400	Acquired		Common stock (1400)	Direct

Footnotes

F1: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.